PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.18
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$11.98M
Enterprise ValueC$11.89M
Total Cash (Recent Filing)C$857.05K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GMP MDMA Supply FocusTargeting GMP-compliant MDMA production positions the firm as a regulated supplier for clinical trials and potential prescription markets. This creates a durable, specialized business model with higher barriers to entry, recurring demand from trial sponsors, and alignment with structural growth in psychedelic therapeutics.
Top-line MomentumSustained TTM revenue growth of ~24.6% signals commercial traction in a nascent market, implying expanding contracts or production volumes. Durable revenue improvement supports operational scaling and validates market demand, reducing execution risk over the next several months if growth persists.
Low LeverageA debt-free balance sheet reduces financial risk and interest obligations, giving management flexibility to prioritize R&D and regulatory compliance. Low leverage provides a buffer against cyclical setbacks and lowers bankruptcy risk, important for a cash-consuming biotech during clinical ramp.
Bears Say
Negative Gross Profit & LossesNegative gross profit indicates the company’s core product costs exceed revenues, a structural margin problem rather than only high overhead. Such a deficit erodes cash and requires fundamental changes to pricing, cost base, or mix to achieve sustainable profitability over the medium term.
Persistent Cash BurnOngoing negative operating and free cash flow mean the business is consuming cash and likely needs external funding unless losses reverse. This creates dilution and financing risk, constraining strategic choices and investment capacity over the next 2–6 months absent sustained margin improvement or new capital.
Eroding Equity ReturnsA small equity base coupled with materially negative returns indicates shareholder capital is being depleted by losses. Continued erosion reduces the firm’s financial cushion, heightens insolvency risk in prolonged stress, and increases dependence on dilutive financing or external support.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.17 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$11.98M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is May 04, 2026 which is in 28 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
Sirona Biochem
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---